Huntington’s Disease and Neural Transplantation
In recent years neural grafting in neurodegenerative diseases has emerged from the realm of the theoretical to that of the practical. In Parkinson’s disease, autografts of adrenal medulla cells to the caudate nucleus of the brain have been shown to produce improvements in the clinical signs of the disease (Madrazo et al., 1987) and patients with idiopathic and MPTP induced Parkinson’s disease have shown improvements following human fetal neural transplants (Freed et al., 1992; Spencer et al., 1992; Widner et al., 1992). Also, neural grafts of embryonic striatal neurons have been shown to partially restore some neurochemical deficits and to ameliorate behavioural and locomotor impairment in animal models of Huntington’s disease (Isacson et al., 1984, 1985, 1986;Hantraye et al., 1992). These findings and others have led to the suggestion that neural transplantation may offer the prospect of a viable strategy for structural repair in Huntington’s disease (Dunnett and Svendsen, 1993).
KeywordsBasal Ganglion Huntington Disease Globus Pallidus Quinolinic Acid Receptor Immunoreactivity
Unable to display preview. Download preview PDF.
- Faull, R.L.M., Waldvogel, H.J., Nicholson, L.F.B., Williams, M.N. and Dragunow, M. (1995). Huntington’s disease and neural transplantation: GABAA receptor changes in the basal ganglia in Huntington’s disease in the human brain and in the quinolinic acid lesioned rat model of the disease following fetal neuron transplants. In: Neurotransmitters in the Human Brain. (D Tracey, J. Stone and G. Paxinos, Eds.) Plenum Press, pp 173-198.Google Scholar
- Freed, C.R., Breeze, R.E., Rosenberg, N.L., Schneck, S.A., Kriek, E., Qi, J.-X., Lone, T., Zhang, Y.-B., Snyder, J.A., Wells, T.H., Ramig, L.O., Thompson, L., Mazziotta, J.C., Huang, S.C., Grafton, S. T., Brooks, D., Sawle, G., Schröter, G., and Ansari, A.A., 1992, Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson’s disease, N. Eng. J. Med. 327:1549–1555.CrossRefGoogle Scholar
- Fritschy, J.-M., Benke, D., Mertens, S., Oertel, W.H., Bachi, T., and Möhler, H., 1992, Five subtypes of type Aγ-aminobutyric acid receptors identified in neurons by double and triple imunofluorescence staining with subunit-specific antibodies, Proc. Natl. Acad. Sci. U.S.A. 89:6726–6730.PubMedCrossRefGoogle Scholar
- Martin, J.B., and Gusella, J.F., 1986, Huntington’s disease, Pathogenesis and management. New Eng. J. Med. 315:1267–1276.Google Scholar
- Penney. J.B., and Pan, H.S., 1986, Quantitative autoradiography of GABA and benzodiazepine binding in studies of mammalian and human basal ganglia function, in: Quantitative Receptor Autoradiography, (C.A. Boast, E.W. Snowhill and C.A. Altar, eds.), Alan R. Liss, New York, pp. 29–52.Google Scholar
- Richards, J.G., Möhler, H., and Haefely, W., 1986, Mapping benzodiazepine receptors in the CNS by radiohistochemistry and immunohistochemistry, in: “Neurohistochemistry: Modern Methods and Applications,” P. Panula, H. Paivarinta and S. Soinila, eds., Alan R. Liss, New York, pp. 629–677.Google Scholar
- Spencer, D.D., Robbins, R.J., Naftolin, F., Phil, D., Marek, K.L., Vollmer, T., Leranth, C., Roth, R.H., Price, L.H., Gjedde, A., Bunney, B.S., Sass, K.J., Elsworth, J.D., Kier, E.L., Makuch, R., Hoffer, P.B., and Redmond, D.E., 1992, Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson’s disease, N. Eng. J. Med. 327:1541–1548.CrossRefGoogle Scholar
- Whitehouse, P.J., Trifiletti, R.R., Jones, B.E., Folstein, S., Price, D.L., Snyder, S.H., and Kuhar, M.J., 1985, Neurotransmitter receptor alterations in Huntington’s disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes, Ann. Neurol. 18:202–210.PubMedCrossRefGoogle Scholar
- Widner, H., Tetrud, J., Rehncrona, S., Snow, B., Brundin, P., Gustavii, B., Björklund, A., Lindvall, O., and Langston, J.W., 1992, Bilateral fetal mesencephalic grafting in two patients with Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), N. Eng. J. Med. 327:1556–1563.CrossRefGoogle Scholar